A fundamental change in drug biodistribution and performance.
TRX’s technology enables targeted oral drug delivery to specific organs, cells and tissues in cancer, CNS and respiratory diseases and diseases of the immune system using a clinically and developmentally proven approach.TRx Technology
Radical approaches to drug absorption, transport and destination.
A disruptive advancement in oral drug uptake, trafficking therapeutics directly to the site of disease, reducing the impact of first-pass metabolism and enhancing production of regulatory immune cells. TRx is leveraging these and other benefits across a growing portfolio of co-development and wholly-owned programmes.TRx Pipeline
- Potential to transform the design, delivery and development of small molecule-based oral therapies
- Exploitation of a novel oral drug uptake channel that utilises existing human biology
- Transcend state-of-the-art oral drug delivery technologies
- Bring unexploitable pharmacology to clinical significance
- Clinically proven technology, rapidly deployable and manufacturable at scale
- Robust and long-term IP protection
- For partners, a proven track record in solving complex pharmacokinetic and pharmacodynamic limitations for lead clinical programmes
Dr Robin Bannister
Robin has over 30 years in Biopharma R&D commercialisation with proven success as a drug developer & entrepreneur, illustrated by the multiple marketed products and successful exits (e.g. Seebri, Arakis) spanning his career to date. Robin has particular scientific expertise in novel biology exploitation via the development of high–value, low-risk products. Robin is an Executive Director of TRx Biosciences Limited.
With over 20 years experience in biopharma product development, John has progressed numerous R&D programmes from concept to market (e.g. Flarin™️). John has developed deep experience in non-clinical & clinical development & regulatory affairs. His scientific expertise spans biology, toxicology, pharmacology, pharmacokinetics & pharmaceutics. John is an Executive Director of TRx Biosciences Limited.